<DOC>
	<DOCNO>NCT00249353</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness CONCERTA® ( methylphenidate hydrochloride , central nervous system ( CNS ) stimulant ) versus placebo treatment Attention Deficit Hyperactivity Disorder ( ADHD ) adolescents..</brief_summary>
	<brief_title>An Effectiveness Safety Study CONCERTA® ( Methylphenidate Hydrochloride ) Treatment Adolescents With Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>The objective study evaluate safety effectiveness CONCERTA® ( methylphenidate hydrochloride ) treatment adolescent Attention Deficit Hyperactivity Disorder ( ADHD ) . This multicenter , randomize , double-blind , placebo-controlled study adolescent age 13-18 diagnosed ADHD . The study consist four phase . The Screening Phase establishes diagnosis ADHD provide one-week washout period without ADHD medication . The Open-Label Titration Phase initiate treatment patient one CONCERTA® 18 mg daily . Thereafter , dose increase approximately every 7 day 18 mg increment ( maximum 72 mg daily ) , individualize dose identify , base clinical judgment investigator . During Double-Blind Phase , subject randomize receive either individualized CONCERTA® dose placebo , period 2 week . Subjects successfully complete Double-Blind Phase eligible receive CONCERTA® 8-week , Open-Label , Follow-up Phase . The primary efficacy measurement total score ADHD Rating Scale , evaluate investigator end Double-Blind Phase . Safety assessment include monitor adverse event , electrocardiogram ( ECG ) , blood pressure , pulse , height weight throughout course study . The study hypothesis CONCERTA® effective placebo treatment Attention Deficit Hyperactivity Disorder adolescent , well tolerate . Titration Phase : CONCERTA® 18 mg take orally , daily , increase approximately every 7 day 18 mg increment maximum daily dose 72 mg. Double-Blind Phase : Individualized dose CONCERTA® placebo 2 week . Open-Label Phase : Individualized dose CONCERTA® 8 week .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Diagnosis Attention Deficit Hyperactivity Disorder ( ADHD ) define Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) Children 's Global Assessment Scale rating 4170 baseline ( Screening Phase ) Subjects know respond methylphenidate Have adverse experience methylphenidate hypersensitivity CONCERTA component Have mark anxiety , tension agitation Have glaucoma , ongoing seizure disorder , psychotic disorder , Tourette 's disorder family history Tourette 's disorder</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>Concerta</keyword>
</DOC>